Johnson & Johnson( )’s earnings reveal just how impressive growth is at the big pharma company, according to TheStreet’s Jim Cramer. He points to J&J’s anti-cancer drug franchise, strong balance sheet, a share gains in consumer products as reasons to like the stock. Cramer also likes the improvement in J&J’s medical devices division.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
